Endocrine Abstracts

Introduction: New medicinal products that have been introduced into first-line therapy for type 2 diabetes mellitus (T2DM) include glucagon-like peptide-1 receptor agonists (GLP-1ra) and dipeptidyl peptidase-4 inhibitors (DPP-4i). These products have been shown to increase beta-cell proliferation. Some studies also demonstrated an increase in pancreatic alpha-cell proliferation. Various sulfonylureas drugs (SU) have been shown to produce different effects on apoptosis pancreat...